Skip to main content
. 2022 Oct 20;9:1023583. doi: 10.3389/fmed.2022.1023583

Figure 1.

Figure 1

Flowchart of patient participation and classification according to metabolic dysfunction and fatty liver disease status. CT-WBS, Computed Tomography Whole Body Scan; FLD, fatty liver disease; MAFLD, metabolic dysfunction–associated fatty liver disease; MD, metabolic dysfunction; MHO, metabolically healthy obesity; MUHO, metabolically unhealthy obesity; OW, overweight; T2D, type 2 diabetes. *Of the initial cohort of 547 patients, 177 were excluded for one or more of the following criteria: personal history of cardiovascular disease (n = 50); personal history of non-ischemic heart disease (n = 25); personal history of cerebrovascular disease (n = 12); active malignancy (n = 14); excessive alcohol consumption (n = 32); advanced liver disease (n = 21) and unavailability to retrieve CT-WBS imaging (n = 3).